|Awarded On||February 21, 2019|
|Title||Growth Signaling in Ewing Sarcoma|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Yuzuru Shiio|
*Pending contract negotiation
Ewing sarcoma is a cancer of bone and soft tissue in children and young adults. Because currently used cytotoxic chemotherapies are not improving the survival of metastatic or recurrent Ewing sarcoma cases, there is an obvious need for a novel molecularly targeted therapy. Ewing sarcoma is primarily driven by a fusion oncoprotein called EWS-FLI1. Therefore, targeting EWS-FLI1 is a rational approach to treat this cancer. Despite many attempts, however, EWS-FLI1-targted therapy has not been developed to date and EWS-FLI1 continues to be “the perfect target without a therapeutic agent.” One way to resolve this conundrum is to find and target the “Achilles’ heel” created by EWS-FLI1. We disc...